Related Experiment Videos
Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models
Abstract:
Previously, we suggested that local human interferon-beta (IFN-beta) gene therapy with replication-defective adenoviral vectors can be an effective cancer treatment. Clinical trials to treat cancers with adenovirus expressing the human IFN-beta gene (IFNB1) has been planned. As a continued effort to explore the mechanisms of action of human IFN-beta gene therapy that can occur in the clinical setting, we tested mouse IFN-beta gene therapy in human xenograft tumors in both ex vivo and in vivo models. Delivery of the mouse IFN-beta gene (Ifnb) caused tumor inhibition; this effect was dependent on the indirect anti-tumor activities of IFN-beta, notably a stimulation of natural killer cells. IFN-beta does not show cross-species activity in its anti-proliferative effect and mouse IFN-beta does not cause as significant an anti-proliferative effect on mouse tumor cells as human IFN-beta causes on human tumor cells. Therefore, we believe that mouse models using either human IFN-beta or mouse IFN-beta gene transfer do not capture all aspects of the action of adenovirus-mediated human IFN-beta gene therapy that may be present in the clinical setting. Due to its multiple mechanisms of action, human IFN-beta gene therapy may be effective in treating human cancers that are either sensitive or resistant to the direct anti-proliferative effect of IFN-beta.
Insights
Local interferon-beta (IFN-beta) gene therapy shows promise for cancer treatment. Mouse models revealed indirect anti-tumor effects, primarily through natural killer cell stimulation, highlighting the need for human-specific studies.
Area of Science:
- Oncology
- Immunology
- Gene Therapy
Background:
- Adenovirus-mediated interferon-beta (IFN-beta) gene therapy is a potential cancer treatment.
- Clinical trials are planned for adenovirus expressing the human IFN-beta gene (IFNB1).
- Understanding the mechanisms of IFN-beta gene therapy in clinical settings is crucial.
Purpose of the Study:
- To investigate the anti-tumor mechanisms of mouse IFN-beta gene therapy in human xenograft models.
- To compare the efficacy of mouse versus human IFN-beta in preclinical models.
- To elucidate the indirect anti-tumor activities of IFN-beta.
Main Methods:
- Ex vivo and in vivo testing of mouse IFN-beta gene therapy in human xenograft tumors.
- Assessment of tumor inhibition and natural killer cell stimulation.
- Evaluation of cross-species anti-proliferative effects of IFN-beta.
Main Results:
- Mouse IFN-beta gene delivery resulted in tumor inhibition.
- The anti-tumor effect was mediated by indirect mechanisms, including natural killer cell stimulation.
- Mouse IFN-beta exhibited limited anti-proliferative effects on human tumor cells, unlike human IFN-beta.
Conclusions:
- Mouse models do not fully replicate the clinical effects of human IFN-beta gene therapy due to lack of cross-species activity.
- Human IFN-beta gene therapy's multiple mechanisms suggest potential efficacy in diverse human cancers.
- IFN-beta gene therapy may overcome resistance to direct anti-proliferative effects in certain cancers.